InspireMD (NSPR) Registration Filing summary

Company overview and business model

• Focuses on developing and commercializing medical devices for carotid artery and vascular disease, notably the CGuard stent platform with MicroNet mesh for embolic protection.

• CGuard EPS is approved in the EU and over 30 countries, with distribution agreements in Asia and recent CE mark recertification in 2024.

• Completed pivotal C-GUARDIANS trial for U.S. FDA approval, showing low adverse event rates; PMA submitted in September 2024, with potential FDA approval in H1 2025.

• Developing new products and indications, including SwitchGuard NPS for neuroprotection and exploring acute stroke applications.

• U.S. market opportunity expanded by CMS coverage for both symptomatic and asymptomatic patients.

Financial performance and metrics

• Net tangible book value as of December 31, 2024: $36.1 million ($1.36 per share).

• After a $75 million offering at $2.68/share, as-adjusted net tangible book value would be $108.6 million ($1.99 per share), with immediate dilution of $0.69 per share to new investors.

• Up to 27,985,074 shares may be outstanding post-offering, excluding significant additional shares issuable upon exercise of warrants, options, and conversion of preferred stock.

Use of proceeds and capital allocation

• Proceeds intended for research and development, sales and marketing, working capital, and general corporate purposes.

• Management has broad discretion over allocation; actual use may vary based on operational needs, clinical trial outcomes, and market conditions.

• Pending use, proceeds may be invested in investment-grade securities or held as cash.